A year after attempting to partner with French drug maker Sanofi – only to have US regulators stop the deal over antitrust concerns – Maze Therapeutics has entered into a similar partnership with Shionogi & Co. Ltd.for the oral Pompe disease drug MZE001.
The companies announced the exclusive worldwide collaboration on 10 May, whereby Shionogi will pay Maze $150m up front, plus undisclosed...